Optimizing therapy early in multiple sclerosis: An evidence-based view
about
Optimizing treatment success in multiple sclerosisMultiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approachThe state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfactionSurvey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical AutoinjectorsRationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patientsStudy design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimodPredicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.The future of multiple sclerosis treatments.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS studyUnderstanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.Diagnostic methods used in searching for markers of atrophy in patients with multiple sclerosis.
P2860
Q26771968-50D61125-ED40-4069-9B1C-99EF13DBEAC7Q28080043-B1E8362A-78AE-4055-B95E-01A14F367AB0Q30275099-44E97A71-0F27-4B22-939A-3C534EF00426Q30830291-B251FE39-FDD3-4864-9732-453037B4557FQ31115496-8A027DC6-E5B1-4DAA-8D22-823E456CE1DBQ33642908-87B28FE7-FE9B-4B9C-A8EE-BB5CB7C2F312Q33764067-337DB83F-C1CB-4239-A236-09EE10D6978EQ36097847-7D09CA79-51B9-4360-BCFF-597D1D62AFF3Q38374486-E5CBA8A1-504E-44A6-B8B6-24FD00256AD0Q38606914-B649CDEE-CFB3-4231-BB7C-801D84FAEA55Q38808485-72081BA3-B650-45B7-B2C7-90E68F2E61EEQ38946338-137FFA3A-3825-49FE-8E4E-3B270DFAF039Q39027028-8E297F42-F64A-4AD3-9C87-8C16AF0BD92EQ39032832-77CF32A1-2BD1-4A67-AC08-F3F6850E04D2Q42375592-0F3FEB41-7DD3-4E56-8AD8-2751F4899189Q44757011-56D4C73C-CE5B-4158-9C46-39444AAB4DFAQ45066717-530DC820-34DD-472D-9CB6-6EA0CF63525AQ48123353-8923754C-6995-45F6-8879-55AAA6E397D7Q49335924-6241E1BE-C60F-4B22-BBEA-616F6903C7C5Q49716124-CBC96A16-60AC-451F-91B5-0CFC6D0D5E2A
P2860
Optimizing therapy early in multiple sclerosis: An evidence-based view
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Optimizing therapy early in multiple sclerosis: An evidence-based view
@ast
Optimizing therapy early in multiple sclerosis: An evidence-based view
@en
Optimizing therapy early in multiple sclerosis: An evidence-based view
@nl
type
label
Optimizing therapy early in multiple sclerosis: An evidence-based view
@ast
Optimizing therapy early in multiple sclerosis: An evidence-based view
@en
Optimizing therapy early in multiple sclerosis: An evidence-based view
@nl
prefLabel
Optimizing therapy early in multiple sclerosis: An evidence-based view
@ast
Optimizing therapy early in multiple sclerosis: An evidence-based view
@en
Optimizing therapy early in multiple sclerosis: An evidence-based view
@nl
P50
P3181
P1476
Optimizing therapy early in multiple sclerosis: An evidence-based view
@en
P2093
Bart Van Wijmeersch
Maria Pia Sormani
P3181
P356
10.1016/J.MSARD.2015.07.007
P407
P577
2015-09-01T00:00:00Z